Clin Cancer Res: VLA4 targets nanoparticles to effectively target the treatment of drug-resistant, incurable myeloma!

In multiple myeloma, drug-resistant cells are the basis for recurrence or progression after chemotherapy.
-DR, which is mediated by cell adhesion, is an established mechanism for myeloma cells (MMC) to survive chemotherapy, and its markers are expressed in residual lesions.
late antigen 4 (Vla4; alpha4 beta1) is a key regulatory factor of CAM-DR, and its expression can affect MMC's sensitivity to drugs.
the study, Francesca et al. hypothesed that drug delivery could be targeted using the VLA4 increase of the drug-resistant MMC, which could help improve the safety and effectiveness of treatment.
molecular structure and pattern map Francesca et al. have synthesized a 20 nm VLA4 targeted beam nanoparticle (V-NP) that carries DiI for dage or a new type of hexaline drug prebiogen (V-CP).
the targeted delivery and therapeutic activity of NP in human or mouse MMC cells and in-place multiple myeloma mouse models.
results of prognosis studies in mice with myeloma with different treatments showed that V-NP was selectively passed on its loaded substances to MMC, both in vivo and in vitro, and chemotherapy increased the intake of V-NP by living MMCs.
resistance in mouse models of myeloma alone with V-CP or in mefalun was good, and the survival time of mice was extended.
V-CP can also reduce the dose demand of mefalun without increasing the overall toxicity, reducing the tumor burden associated with sub-optimal dose.
, V-CP may be a safe and effective strategy for preventing or treating relapses or resuscable myeloma.
V-NP-targeted drug-resistant cells may provide a new way to treat environmentally induced drug-resistant cancers.